In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2005/001014.

This listing of claims will replace all prior versions and listings of claims in this application.

- 1 (original). A pharmaceutical composition in the form of a unit dosage comprising 1 to 60 mg (+)-erythro-mefloquine, substantially free of the opposite enantiomer.
- 2 (currently amended). [[A]] <u>The</u> composition according to claim 1, wherein the unit dosage is a tablet comprising a carrier and/or excipient.
- 3 (currently amended). [[A]] <u>The</u> composition according to claim 1—or claim—2, wherein the unit dosage comprises up to 40 mg (+)-erythro-mefloquine.
- 4 (currently amended). [[A]] <u>The</u> composition according to claim 3, wherein the unit dosage comprises up to 20 mg (+)-erythro-mefloquine.
- 5 (currently amended). [[A]] <u>The</u> composition according to claim 3, wherein the unit dosage comprises up to 15 mg (+)-erythro-mefloquine.
- 6 (currently amended). [[A]] <u>The composition according to any preceding claim 1</u>, wherein the unit dosage comprises at least 5 mg (+)-erythro-mefloquine.
- 7 (currently amended). Use of (+) erythro-mefloquine for the manufacture of a composition according to any preceding claim, for use in A method for the treatment of an inflammatory condition wherein said method comprises administering, to a subject in need of such treatment, a pharmaceutical composition in the form of a unit dosage comprising 1 to 60 mg (+)-erythro-mefloquine, substantially free of the opposite enantiomer.
- 8 (currently amended). [[Use]] <u>The method</u> according to claim 7, wherein the condition is osteoarthritis.

- 9 (currently amended). [[Use]] <u>The method</u> according to claim 7, wherein the condition is rheumatoid arthritis.
- 10 (currently amended). Use according to any of claims 7 to 9 The method according to claim 7, wherein the condition is also treated with an anti-TNF antibody.
- 11 (currently amended). Use according to claims 7 to 10 The method according to claim 7, wherein the subject of treatment is also receiving an immunosuppressant.
- 12 (currently amended). [[Use]] <u>The method</u> according to claim 11, wherein the immunosuppressant is methotrexate.
- 13 (original). A product comprising (+)-erythro-mefloquine and an anti-TNF antibody, as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition.
- 14 (original). A product comprising (+)-erythro-mefloquine and an immunosuppressant as a combined preparation for simultaneous, separate or sequential use in the treatment of an inflammatory condition and where immunosuppression is also required.
- 15 (currently amended). [[A]] <u>The</u> product according to claim 14, wherein the immunosuppressant is methotrexate.